# First in Human Study of TORL-3-600 in Participants With Advanced Cancer

> **NCT05948826** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **TORL Biotherapeutics, LLC** · enrollment: 70 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Colorectal Cancer

## Interventions

- **DRUG:** TORL-3-600

## Key facts

- **NCT ID:** NCT05948826
- **Lead sponsor:** TORL Biotherapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-29
- **Primary completion:** 2026-06-25
- **Final completion:** 2026-09-15
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05948826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05948826, "First in Human Study of TORL-3-600 in Participants With Advanced Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05948826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*